Ampio Pharmaceuticals Inc
OTC:AMPE
Ampio Pharmaceuticals Inc
Research & Development
Ampio Pharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ampio Pharmaceuticals Inc
OTC:AMPE
|
Research & Development
-$2.3m
|
CAGR 3-Years
34%
|
CAGR 5-Years
19%
|
CAGR 10-Years
18%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Ampio Pharmaceuticals Inc
Glance View
Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Englewood, Colorado and currently employs 8 full-time employees. The company went IPO on 2011-05-19. The firm is focused on the preclinical development of AR-300, and is conducting studies to evaluate the efficacy of AR-300 in osteoarthritis-related pain. The firm is primarily targeting the clinical development of AR-300 for the treatment of osteoarthritis of the knee (OAK). AR-300 is a small-molecule formulation that has demonstrated anti-inflammatory properties in vitro and protection of cartilage in preclinical rat meniscal tear studies.
See Also
What is Ampio Pharmaceuticals Inc's Research & Development?
Research & Development
-2.3m
USD
Based on the financial report for Dec 31, 2023, Ampio Pharmaceuticals Inc's Research & Development amounts to -2.3m USD.
What is Ampio Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 10Y
18%
Over the last year, the Research & Development growth was 71%. The average annual Research & Development growth rates for Ampio Pharmaceuticals Inc have been 34% over the past three years , 19% over the past five years , and 18% over the past ten years .
